Abiopharma

🔍 Strout Gordon Lewis Jr (Director)

Company: Capstone Holding Corp. (CAPS)

Report Date: 2025-03-07

Detailed Transactions and Holdings:

• Acquired 822,128 shares of Common Stock (Direct)
  Date: 2025-03-07 | Code: J | equity_swap_involved: 0 | shares_owned_after: 822,128.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 41,500 shares of Common Stock at $4.0 per share (Direct)
  Date: 2025-03-07 | Code: P | equity_swap_involved: 0 | shares_owned_after: 41,500.00 | transaction_form_type: 4
• Acquired 142,500 shares of Common Stock (Direct)
  Date: 2026-03-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 184,000.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 357,810 shares of Common Stock (Direct)
  Date: 2026-08-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 541,810.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: On March 7, 2025, pursuant to a Master Exchange Agreement entered into among the Issuer, its operating subsidiary, TotalStone, LLC ("TotalStone"), and TotalStone's Class B and Class C Members, all of the Preferred Interests in TotalStone previously owned by the Reporting Person were exchanged for 822,128 shares of the Issuer's Common Stock.
• F2: THE REPORTED SHARES ARE UNVESTED RESTRICTED STOCK AND MAY NOT BE SOLD, TRANSFERRED OR PLEDGED. Including 142,500 and 357,810 shares of common stock granted to the Reporting Person on March 30, 2026 and August 7, 2026, respectively, as restricted stock awards, for no consideration, under the Capstone Holding Corp. 2025 Stock Incentive Plan, as amended. The restricted stock awards will vest in full only upon the Reporting Person's Separation Date, as defined in the Reporting Person's Master Restricted Stock Agreement.